SYK: Stryker Corporation Stock

by  •  • Comments Off on SYK: Stryker Corporation Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 124,584.85
Enterprise Value ($M) 134,639.85
Book Value ($M) 18,593.00
Book Value / Share 48.87
Price / Book 6.70
NCAV ($M) -8,801.00
NCAV / Share -23.13
Price / NCAV -14.16

Profitability (mra)
Return on Invested Capital (ROIC) 0.10
Return on Assets (ROA) 0.09
Return on Equity (ROE) 0.19

Liquidity (mrq)
Quick Ratio 0.97
Current Ratio 1.58

Balance Sheet (mrq) ($M)
Current Assets 12,487.00
Assets 39,881.00
Liabilities 21,288.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 20,498.00
Operating Income 4,131.00
Net Income 3,165.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 3,680.00
Cash from Investing -962.00
Cash from Financing -1,594.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 8.20 2.99
02-12 13G/A Greenleaf Trust 4.90 -5.77
01-29 13G/A BlackRock Inc. 6.60 1.76

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-19 289,615 1,367,125 21.18
2024-04-18 429,895 2,143,604 20.05
2024-04-17 261,335 1,066,062 24.51
2024-04-16 234,240 1,239,358 18.90
2024-04-15 129,914 1,087,797 11.94

(click for more detail)

Similar Companies
RMD – ResMed Inc. STE – STERIS plc
STVN – Stevanato Group S.p.A. TFX – Teleflex Incorporated
WST – West Pharmaceutical Services, Inc.


Financial data and stock pages provided by
Fintel.io